Naveena S. Veeranagaiah

Naveena S. Veeranagaiah

Auto-generated profile, based on publicly available information

Naveena S. Veeranagaiah

Department of Chemistry, Central University of Karnataka, Kalaburagi-585 367, Karnataka, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
DPDinesha P
Dinesha P
SNShivakumar Naik
Shivakumar Naik
UDUdaya Kumar D
Udaya Kumar D
RCRevanasiddappa B C
Revanasiddappa B C
VRVenkatesh Ranjan
Venkatesh Ranjan
NVNaveena S. Veeranagaiah
Naveena S. Veeranagaiah
A new set of imidazo[1,2-a]pyrimidine-thiazole hybrids were developed through a molecular hybridization concept. Three compounds exhibited potent anti-TB activity with MIC of 1.6 μg mL−1.

21 October 2026 in Chemistry & Biodiversity
Verified
Journal Article
Open access
PDF file
DPDinesha P
Dinesha P
SNShivakumar Naik
Shivakumar Naik
UDUdaya Kumar D
Udaya Kumar D
MDMaithilee S. Dhekale
Maithilee S. Dhekale
SVSampat Parayya Vibhutimath
Sampat Parayya Vibhutimath
NVNaveena S. Veeranagaiah
Naveena S. Veeranagaiah
This work reports the design and development of two series of imine‐linked imidazo[1,2‐ a ]pyrimidine‐thiazole/1,3,4‐thiadiazole derivatives using a molecular hybridization approach as anti‐tubercular agents. A total of thirty‐seven new hybrid compounds (B1‐B37) were synthesized and characterized. One final molecule, B20, was structurally confirmed by single‐crystal x‐ray diffraction analysis. All the final compounds (B1‐B37) were tested for activity against the Mycobacterium tuberculosis H37Rv strain. Compounds B5, B26, and B30 exhibited significant inhibitory effects, with MICs of 12.5, 12.5, and 6.25 µg/mL, respectively. All novel final compounds also displayed effective antibacterial action against four bacterial strains S. aureus , E. coli , B. subtilis , and P. aeruginosa . Toxicity tests on mouse fibroblast (L929) cell lines revealed that the highly active anti‐TB compounds (B5, B26, and B30) were nontoxic. Furthermore, the outcomes of the in silico ADME evaluation, DFT analysis, molecular docking studies (targeting CYP121 and InhA), and dynamic simulation demonstrated the potent compounds' great potential as prospective scaffolds for the development of novel antitubercular drugs.